Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 8:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Altace Clear all
Completed Phase 2 Interventional

Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)

NCT00054938
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus
Interventions
pravastatin, aspirin, ramipril, Vitamins: B6, B12, and folate, heart health educational program
Drug · Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 23, 2013 · Synced Sep 6, 2026, 8:49 AM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 6, 2026, 8:49 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes

NCT00574834
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Ramipril, HCTZ-hydrochlorothiazide, Ramipril+HCTZ
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 6, 2026, 8:49 AM EDT
Completed Phase 3 Interventional

Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension

NCT00281593
View directory record Official record
Conditions
Hypertension
Interventions
Telmisartan, Ramipril
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
70
States / cities
Glendale, Arizona • Tempe, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 6, 2026, 8:49 AM EDT
Not listed Phase 2 Interventional

Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy

NCT02791958
View directory record Official record
Conditions
Hypertension
Interventions
Cardiovascular Fixed Dose Combination Pill AAR, Atorvastatin 40 mg, Ramipril 10 mg
Drug
Lead sponsor
Ferrer Internacional S.A.
Industry
Eligibility
18 Years to 74 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Sep 6, 2026, 8:49 AM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension

NCT00631917
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Ramipril, Placebo to Ramipril, Placebo to Aliskiren
Drug · Other
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Sep 6, 2026, 8:49 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Ramipril for the Treatment of Oligospermia

NCT01856361
View directory record Official record
Conditions
Oligospermia, Teratospermia, Asthenozoospermia, Male Infertility
Interventions
Ramipril, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Sep 6, 2026, 8:49 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly

NCT00368277
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Ramipril, Hydrochlorothiazide, Amlodipine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
65 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2011 · Synced Sep 6, 2026, 8:49 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

NCT00153101
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Telmisartan, Combination of Telmisartan and Ramipril, Ramipril
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
55 Years and older
Enrollment
31,546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
100
States / cities
Athens, Alabama • Birmingham, Alabama • Phoenix, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 6, 2026, 8:49 AM EDT
Completed Phase 4 Interventional Results available

Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery

NCT01669434
View directory record Official record
Conditions
Hypotension on Induction
Interventions
ACEI continuation, ACEI omission
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 90 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 24, 2023 · Synced Sep 6, 2026, 8:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Ramipril 10 mg Capsules Administered Orally as a Sprinkle on Applesauce

NCT00863915
View directory record Official record
Conditions
Healthy
Interventions
Ramipril10 mg Capsules, single dose, Atlace® 10 mg capsules, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2010 · Synced Sep 6, 2026, 8:49 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)

NCT00141778
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Placebo, Ramipril, Spironolactone
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Sep 6, 2026, 8:49 AM EDT
Completed Phase 2 Interventional Results available

Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis

NCT00732069
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis, Complication of Hemodialysis
Interventions
Placebo, Ramipril, Valsartan
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Sep 6, 2026, 8:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fed Conditions

NCT00864162
View directory record Official record
Conditions
Healthy
Interventions
Ramipril10 mg Capsules, single dose, Atlace® 10 mg capsules, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2010 · Synced Sep 6, 2026, 8:49 AM EDT
Completed Not applicable Interventional Results available

Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

NCT02130687
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hypertension
Interventions
Placebo, Sitagliptin, Aprepitant, Mixed Meal Test (MMT)
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 6, 2026, 8:49 AM EDT
Completed Phase 2 Interventional

Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation

NCT00005928
View directory record Official record
Conditions
Atherosclerosis, Coronary Disease, Vasculitis
Interventions
Ramipril
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 6, 2026, 8:49 AM EDT
Completed Phase 4 Interventional

Treatment of Pediatric Hypertension With Altace Trial

NCT00044265
View directory record Official record
Conditions
Hypertension
Interventions
ramipril
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 16 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • Augusta, Georgia + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Sep 6, 2026, 8:49 AM EDT
Terminated Phase 2 Interventional Results available

Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors

NCT01234922
View directory record Official record
Conditions
Hypertension, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
lisinopril, losartan potassium, laboratory biomarker analysis, benazepril hydrochloride, ramipril
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Sep 6, 2026, 8:49 AM EDT
Completed No phase listed Observational

Replication of the ONTARGET Antihypertensive Trial in Healthcare Claims Data

NCT04354350
View directory record Official record
Conditions
Hypertension
Interventions
Ramipril, Telmisartan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
55 Years and older
Enrollment
63,744 participants
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 6, 2026, 8:49 AM EDT
Completed Not applicable Interventional Results available

Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy

NCT01078363
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
ramipril, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
12 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Sep 6, 2026, 8:49 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity

NCT00608465
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Eplerenone, Ramipril
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 6, 2026, 8:49 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 6, 2026, 8:49 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Impact of Diabetes on Left Ventricular Remodeling

NCT01052272
View directory record Official record
Conditions
Diabetes
Interventions
Ramipril, Candesartan cilexetil, Allopurinol
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced Sep 6, 2026, 8:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Ramipril 10 mg Capsules Under Fed Conditions

NCT00702260
View directory record Official record
Conditions
Hypertension
Interventions
Ramipril
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 6, 2026, 8:49 AM EDT